Heliyon, Год журнала: 2025, Номер 11(2), С. e41980 - e41980
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
3
Antiviral Research, Год журнала: 2025, Номер unknown, С. 106123 - 106123
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Viruses, Год журнала: 2023, Номер 15(9), С. 1886 - 1886
Опубликована: Сен. 6, 2023
The SARS-CoV-2 entry into host cells is mainly mediated by the interactions between viral spike protein (S) and ACE-2 cell receptor, which are highly glycosylated. Therefore, carbohydrate binding agents may represent potential candidates to abrogate virus infection. Here, we evaluated in vitro anti-SARS-CoV-2 activity of two mannose-binding lectins isolated from Brazilian plants Canavalia brasiliensis Dioclea violacea (ConBR DVL). These inhibited Wuhan-Hu-1 strain variants Gamma Omicron infections, with selectivity indexes (SI) 7, 1.7, 6.5, respectively for ConBR; 25, 16.8, 22.3, DVL. ConBR DVL over 95% early stages infection, strong virucidal effect, also protected infection presented post-entry inhibition. presence mannose resulted complete lack DVL, recovering titers. ATR-FTIR, molecular docking, dynamic simulation S either indicated predicted energies -85.4 -72.0 Kcal/Mol, respectively. Our findings show that possess activities against SARS-CoV-2, potentially interacting glycans blocking cells, representing development novel antiviral drugs.
Язык: Английский
Процитировано
7
Clinical Pharmacokinetics, Год журнала: 2024, Номер 63(7), С. 919 - 944
Опубликована: Июнь 18, 2024
Язык: Английский
Процитировано
2
Tropical Diseases Travel Medicine and Vaccines, Год журнала: 2024, Номер 10(1)
Опубликована: Ноя. 14, 2024
Dengue virus (DENV) is a mosquito-borne that causes dengue fever, significant public health concern in many tropical and subtropical regions. endemic more than 100 countries, primarily regions of the world. Each year, up to 400 million people get infected with dengue. Approximately sick from infection, 40,000 die severe Unfortunately, vaccine development also marred various complicating factors, as forefront candidate performed unsatisfactorily. Moreover, only licensed (Dengvaxia) for children 9 through 16 years age available just few countries. The treatment difficulties are compounded by absence an effective antiviral agent. Exploring plant-based therapeutics laboratory clinical application involves multi-stage process, encompassing scientific disciplines. Individual investigators have screened wide range plant extracts or compounds potential activity against DENV. In vitro studies help identify candidates exhibit inhibitory effects on viral replication. Some most promising medicinal plants showing DENV include Andrographis paniculate, Acorus calamus, Cladogynos orientalis. Further studies, both animal models (in vivo), elucidate mechanisms action which identified exert effects. Medicinal such Carica papaya, Cissampelos pareira, Ipomea batata exhibited potent platelet-enhancing activities while Azadirachta indica Curcuma longa showed vivo studies. Based positive preclinical results, researchers design trials. This careful planning trial phases, patient recruitment criteria, ethical considerations, endpoints. important efficacy safety trials papaya pareira. review suggests several exist be turned into drugs treat infection. However, addition developing synthetic therapies vector management strategies should made robust, emphasizing need focus reducing disease incidence.
Язык: Английский
Процитировано
1
Pharmaceutics, Год журнала: 2024, Номер 16(10), С. 1262 - 1262
Опубликована: Сен. 27, 2024
Background. The emergence, global spread, and persistence of SARS-CoV-2 resulted in an unprecedented need for effective antiviral drugs. Throughout the pandemic, various drug development treatment strategies were adopted, including repurposing antivirals designed other viruses along with a multitude drugs varying mechanisms action (MoAs). Furthermore, multidrug against COVID-19 is ongoing topic merits further investigation. Method/Objectives. We assessed efficacy reconstituted human nasal epithelia, using combinations molnupiravir nirmatrelvir as baseline, adding suboptimal concentrations either GS-441524 or ivermectin, attempting to increase overall activity while lowering therapeutic dose. Results. Nirmatrelvir combined molnupiravir, GS-441524, ivermectin at show increased compared single treatment. No triple showed improved inhibition replication beyond what was observed double treatments. Conclusions. In general, we that addition third compound not beneficial activity, exhibit over
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0